SAN DIEGO — Semaglutide (Wegovy) reduced albuminuria in patients with overweight or obesity and chronic kidney disease (CKD) but without type 2 diabetes, a randomized trial showed.
Among 101 patients, those who received 2.4-mg semaglutide for 24 weeks had a 52.1% (95% CI -65.5 to -33.4, P